Kairos Pharma, Ltd. Common Stock (KAPA)
0.8670
+0.0140 (1.64%)
NYSE · Last Trade: Apr 27th, 7:36 PM EDT
Detailed Quote
| Previous Close | 0.8530 |
|---|---|
| Open | 0.8452 |
| Bid | 0.8510 |
| Ask | 0.9530 |
| Day's Range | 0.8400 - 0.8900 |
| 52 Week Range | 0.8021 - 4.000 |
| Volume | 49,877 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 145,373 |
Chart
News & Press Releases
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · April 25, 2025
Via Benzinga · April 25, 2025
Via Benzinga · April 25, 2025
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recent progress and strategic developments. The company is advancing two clinical trials for lead candidate ENV105 in prostate and EGFR-dependent non-small cell lung cancers, with safety and interim efficacy results expected in Q2 2025. Kairos is also developing KROS101, an immune response modulator, with recent data presented at key oncology conferences. Supported by non-dilutive government grants, an expanding trial network, and analyst coverage from firms including EF Hutton and HC Wainwright, Kairos emphasized its strong financial position and robust IP portfolio extending into the 2030s.
Via Investor Brand Network · April 24, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.:
By Kairos Pharma, Ltd · Via Business Wire · April 24, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
Kairos Pharma (NYSE American: KAPA) announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer. The study focuses on patients developing resistance to osimertinib, aiming to identify those who may benefit from early intervention with ENV105. The funding will support research in Dr. Neil Bhowmick’s lab and aligns with Kairos’ strategy to improve long-term outcomes through targeted therapy and precision monitoring.
Via Investor Brand Network · April 17, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense (“DoD”) is providing $876,000 to advance a strategy to identify patients that are starting to develop resistance at an early stage. The grant was awarded to identify biomarkers for the Company’s clinical study to address the major challenge in achieving a lasting cure for lung cancer patients. The grant was awarded to Cedars-Sinai Medical Center to support research in Dr. Neil Bhowmick’s laboratory to identify biomarkers of patients with non-small cell carcinoma who have developed resistance to Osimertinib. This will provide a means to identify those patients who will benefit from ENV105.
By Kairos Pharma, Ltd · Via Business Wire · April 17, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · April 4, 2025
Via Benzinga · April 4, 2025
Via Benzinga · April 3, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced completion of the safety lead-in for its Phase 2 trial evaluating ENV105 in combination with apalutamide for metastatic, castration-resistant prostate cancer. The trial will now proceed with patient randomization to assess apalutamide alone versus the combination therapy. Safety and efficacy data from the lead-in phase are expected in the first half of 2025. The company is also validating biomarkers to identify patients most likely to benefit from ENV105 and continues enrollment at cancer centers in Los Angeles and Salt Lake City.
Via Investor Brand Network · March 31, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the “Company’”), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial, titled, “Phase II study of Apalutamide with Carotuximab (ENV105) in Metastatic, Castration Resistant Prostate Cancer,” began with the safety lead-in, which combined apalutamide, a standard of care for prostate cancer, with the Company’s compound ENV105.
By Kairos Pharma, Ltd · Via Business Wire · March 31, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, reported recent activity at major scientific gatherings and announced upcoming conference appearances. The company presented research on its GITR agonist KROS 101 at the Society for Immunotherapy of Cancer Spring Meeting on March 12, participated in BIO Europe from March 17 to 19, and will attend the Fierce Pharma Engage meeting in San Diego from April 29 to May 1. An abstract has also been accepted for presentation at the American Society of Clinical Oncology Annual Meeting in Chicago from May 20 to June 5. In addition, Maxim Group initiated research coverage of the company on March 27. CEO John Yu highlighted progress in Phase 2 trials for ENV105 and advancements in its KROS platform as signs of growing momentum in oncology innovation.
Via Investor Brand Network · March 28, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events.
By Kairos Pharma, Ltd · Via Business Wire · March 27, 2025
Via Benzinga · March 25, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Publishes Findings on Overcoming NSCLC Drug Resistance
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has published a peer-reviewed study highlighting a potential breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC). The study, published in Drug Resistance Updates, identifies CD105 (endoglin) as a key factor in mediating resistance to osimertinib, a frontline treatment for EGFR-mutant NSCLC. Preclinical models demonstrated that targeting CD105 with ENV105 (carotuximab), a CD105-neutralizing antibody, restored treatment sensitivity, suggesting a novel combination therapy strategy to overcome drug resistance. Kairos Pharma is currently evaluating this approach in clinical trials.
Via Investor Brand Network · March 20, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a peer-reviewed publication highlighting a potentially significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC) patients. Recent findings published in Drug Resistance Updates highlight the critical role of CD105 (endoglin) in mediating resistance to osimertinib, a frontline treatment for EGFR-mutant NSCLC. The study, titled, “CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer,” demonstrated that CD105 expression is upregulated as a mechanism of therapy resistance, correlating with poor prognosis in patients.
By Kairos Pharma, Ltd · Via Business Wire · March 20, 2025
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Presents Positive Preclinical Data on KROS 101 and KROS 401 at AACR IO Conference
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, presented preclinical data on its investigational compounds KROS 101 and KROS 401 at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference held in Los Angeles from Feb. 23-26, 2025. The data highlighted KROS 101’s ability to inhibit tumor growth and boost T cell responses in melanoma and glioblastoma models, while KROS 401 demonstrated potential in reprogramming macrophages to counter tumor growth in glioma-bearing mice. Company executives emphasized the significance of these findings in advancing immunotherapy approaches for hard-to-treat cancers.
Via Investor Brand Network · February 26, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research Immuno-Oncology (AACR IO) conference held in Los Angeles from February 23-26, 2025. The data highlighted positive preclinical outcomes with the Company’s glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist KROS101 in melanoma and glioblastoma as well as its peptide inhibitor for macrophages KROS 401 in glioma animal models.
By Kairos Pharma, Ltd · Via Business Wire · February 26, 2025
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures $600K in Funding for ENV205 Development
Kairos Pharma (NYSE American: KAPA) announced that Cedars-Sinai Medical Center, through its academic partnership with the company, has received $600,000 from the Department of Defense Lung Cancer Research Program to support the development of ENV205. This first-in-class therapy aims to counteract chemotherapy drug resistance and cachexia, a severe muscle-wasting condition affecting cancer patients. The funding will accelerate research efforts to enhance the effectiveness of cancer treatments by targeting key metabolic pathways. CEO Dr. John Yu emphasized the company’s strategy of leveraging non-dilutive federal funding to drive drug development.
Via Investor Brand Network · February 18, 2025
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205, a groundbreaking new drug to treat chemotherapy drug resistance and cachexia.
By Kairos Pharma, Ltd · Via Business Wire · February 18, 2025
Via Benzinga · February 13, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Adds Huntsman Cancer Institute to Phase 2 Trial for Prostate Cancer Therapy
Kairos Pharma (NYSE American: KAPA) has added Huntsman Cancer Institute in Salt Lake City as a site for its Phase 2 clinical trial of ENV105 for castrate-resistant prostate cancer. The trial, supported by the National Cancer Institute, evaluates ENV105 in combination with apalutamide. Chief Scientific Officer Dr. Neil Bhowmick emphasized Huntsman’s role in expanding patient access and advancing biomarker research. CEO Dr. John Yu highlighted the addition as a key milestone in addressing resistance to hormone therapy in prostate cancer treatment.
Via Investor Brand Network · February 11, 2025
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.
By Kairos Pharma, Ltd · Via Business Wire · February 11, 2025